Research and development of escitalopram detection kit (direct chemiluminescence method)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400081996

Enrollment

Unknown

Registered

2024-03-18

Start date

2024-03-23

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have been taking escitalopram continuously for 7 days or more.

Exclusion criteria

Exclusion criteria: 1) If the sample is stored for more than the expiration date (2-8 ?, stored in dark for more than 4 days); 2) Those who cannot take care of themselves in life; 3) Individuals with no autonomous consciousness or extremely unstable emotions; 4) Other unable to cooperate with sampling and information collectors;

Design outcomes

Primary

Measure	Time frame
Blood concentration of escitalopram by fluorescence immunochromatography;	—

Secondary

Measure	Time frame
Blood concentration of escitalopram by mass spectrometry;	—

Countries

China

Contacts

Public ContactMinmin Shen

Huzhou Central Hospital

15715896580@126.com+86 572 255 5138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026